Virax Biolabs Group Ltd - Ordinary Shares - Class A
VRAX
Get informed when a big investor buys or sells
+ FollowMarket Cap$821.06K
Close$
$1.23
413.7% upside
Current Fair Value
413.7% upsideUndervalued by 413.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $821,064.00 |
|---|---|
| Enterprise Value | $-1,975,497.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.96 |
| Beta | 1.05 |
| Outstanding Shares | 4,763,003 |
Return
| Return on Equity | -230.12% |
|---|---|
| Return on Assets | -213.89% |
| Return on Invested Capital | -227.10% |
Valuation & Multiples
| P/E Ratio | -0.16 |
|---|---|
| PEG | 1.05 |
| Price to Sales | - |
| Price to Book Ratio | 0.24 |
| Enterprise Value to Revenue | -22.49 |
| Enterprise Value to EBIT | 0.16 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.28 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
June 3, 2026
EPS Estimate
$-0.07
Average shareholder expectationRevenue Estimate
$1,401
Average shareholder expectationNext Earnings Call
Expected Date
December 2, 2026
EPS Estimate
$-0.10
Average shareholder expectationRevenue Estimate
$10.00 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.73%▼ 2.33% |
|---|---|
| Total Invested | $12,085▼ 78.81% |
| Investors Holding | 5▲ 1.00% |
ESG Score
No data